I would expect an acceleration starting now. With our man on the road every day visiting hospitals and getting Leronlimab to “ top of mind” physicians who are treating s/c patients is a critical new role. We also have the group of doctors just formed by Cytodyn who are experts In Treating the virus with Leronlimab who can either proactively call hospitals in the study or answer questions of the physicians who are now getting on board with the trial. The revelation in yesterday’s cc that we were 4th or 5th on the list at hospitals , I believe this information provides the insights on how important Pharma sales organizations are and the fact that Big Pharma have brands that doctors trust because of track histories using their drugs on their patients. We are the new small Biotech firm with zero sales people...our guy right now is the frontline serving that role in educating the docs plus he has the support of the new medical team Cytodyn formed to help educate the docs . The other leg to this is the UK spinning their trial up , hopefully quickly. With all these factors in place,I don’t feel it’s unreasonable to get 1.5 enrollees per day across the multitude of hospitals now in the trial both here and the UK. That would put us around 30 to 35 days out to having the numbers we need for the next initial review 42 days later.